Evidence map›Paper›PMID 41620327›Full record

ArticleNeurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics2026

Single-dose psilocybin promotes cell-type-specific changes of neurons in the orbitofrontal cortex.

Ziran Huang, Xiaoyan Wei, Yihui Wang, Jing Tian, Jihui Dong, Bo Liang, Lin Lu, Wen Zhang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Ziran HuangDepartment of Neurobiology, School of Basic Medical Sciences and National Institute on Drug Dependence, Peking University, Beijing, 100191, China.
Xiaoyan WeiDepartment of Neurobiology, School of Basic Medical Sciences and National Institute on Drug Dependence, Peking University, Beijing, 100191, China.
Yihui WangDepartment of Neurobiology, School of Basic Medical Sciences and National Institute on Drug Dependence, Peking University, Beijing, 100191, China.
Jing TianDepartment of Neurobiology, School of Basic Medical Sciences and National Institute on Drug Dependence, Peking University, Beijing, 100191, China.
Jihui DongDepartment of Neurobiology, School of Basic Medical Sciences and National Institute on Drug Dependence, Peking University, Beijing, 100191, China.
Bo LiangSchool of Electrical Engineering and Computer Science, University of North Dakota, Grand Forks, ND, 58202, USA.
Lin LuPeking University Sixth Hospital, Peking University Institute of Mental Health, NHC Key Laboratory of Mental Health (Peking University), National Clinical Research Center for Mental Disorders (Peking University Sixth Hospital), Peking-Tsinghua Center for Life Sciences and PKU-IDG/McGovern Institute for Brain Research, Peking University, Beijing, 100191, China.
Wen ZhangDepartment of Neurobiology, School of Basic Medical Sciences and National Institute on Drug Dependence, Peking University, Beijing, 100191, China; College of Integrative Chinese and Western Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, 301617, China. Electronic address: zhangw@hsc.pku.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Recent clinical breakthroughs hold great promise for the application of psilocybin in the treatments of psychological disorders, such as depression, addiction, and obsessive-compulsive disorder. Psilocybin is a psychedelic whose metabolite, psilocin, is a 5-HT

Indexed as

HallucinogensNeuronsPrefrontal CortexPsilocybinSerotonin 5-HT2 Receptor AgonistsAnimalsMaleMiceMice, Inbred C57BLPyramidal CellsReceptor, Serotonin, 5-HT2AHallucinogensPsilocybinReceptor, Serotonin, 5-HT2ASerotonin 5-HT2 Receptor Agonists5-HT(2A) receptorNeuronOrbitofrontal cortexPsilocybin

Identifiers

PMID41620327
PMCPMC12976539

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.